Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 44

Cited In for PubMed (Select 22521071)


Clinical use of Insulin Degludec: Practical Experience and Pragmatic Suggestions.

Kalra S, Gupta Y.

N Am J Med Sci. 2015 Mar;7(3):81-5. doi: 10.4103/1947-2714.153918. Review.


Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes.

Thalange N, Deeb L, Iotova V, Kawamura T, Klingensmith G, Philotheou A, Silverstein J, Tumini S, Ocampo Francisco AM, Kinduryte O, Danne T.

Pediatr Diabetes. 2015 May;16(3):164-76. doi: 10.1111/pedi.12263. Epub 2015 Feb 12.


Glucose-responsive insulin activity by covalent modification with aliphatic phenylboronic acid conjugates.

Chou DH, Webber MJ, Tang BC, Lin AB, Thapa LS, Deng D, Truong JV, Cortinas AB, Langer R, Anderson DG.

Proc Natl Acad Sci U S A. 2015 Feb 24;112(8):2401-6. doi: 10.1073/pnas.1424684112. Epub 2015 Feb 9.


Modern basal insulin analogs: An incomplete story.

Singh AK, Gangopadhyay KK.

Indian J Endocrinol Metab. 2014 Nov;18(6):784-93. doi: 10.4103/2230-8210.140239. Review.


Advances in management of type 1 diabetes mellitus.

Aathira R, Jain V.

World J Diabetes. 2014 Oct 15;5(5):689-96. doi: 10.4239/wjd.v5.i5.689. Review.


Treatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 inhibitors.

Tomkin GH.

World J Diabetes. 2014 Oct 15;5(5):636-50. doi: 10.4239/wjd.v5.i5.636. Review.


A review of the pharmacological properties of insulin degludec and their clinical relevance.

Haahr H, Heise T.

Clin Pharmacokinet. 2014 Sep;53(9):787-800. doi: 10.1007/s40262-014-0165-y. Review.


Insulin degludec/insulin aspart combination for the treatment of type 1 and type 2 diabetes.

Dardano A, Bianchi C, Del Prato S, Miccoli R.

Vasc Health Risk Manag. 2014 Aug 5;10:465-75. doi: 10.2147/VHRM.S40097. eCollection 2014. Review.


Is insulin degludec a more effective treatment for patients using high doses of insulin glargine but not attaining euglycemia? Some case reports from India.

Sinha B, Gangopadhyay KK, Ghosal S.

Diabetes Metab Syndr Obes. 2014 Jun 23;7:225-8. doi: 10.2147/DMSO.S63878. eCollection 2014.


Insulin degludec versus insulin glargine in type 1 and type 2 diabetes mellitus: a meta-analysis of endpoints in phase 3a trials.

Vora J, Christensen T, Rana A, Bain SC.

Diabetes Ther. 2014 Dec;5(2):435-46. doi: 10.1007/s13300-014-0076-9. Epub 2014 Aug 1.


The evolution of insulin glargine and its continuing contribution to diabetes care.

Hilgenfeld R, Seipke G, Berchtold H, Owens DR.

Drugs. 2014 Jun;74(8):911-27. doi: 10.1007/s40265-014-0226-4.


Insulin degludec compared with insulin glargine in insulin-naïve patients with type 2 diabetes: A 26-week, randomized, controlled, Pan-Asian, treat-to-target trial.

Onishi Y, Iwamoto Y, Yoo SJ, Clauson P, Tamer SC, Park S.

J Diabetes Investig. 2013 Nov 27;4(6):605-12. doi: 10.1111/jdi.12102. Epub 2013 Jun 3.


Insulin degludec in Japanese patients with type 1 diabetes mellitus: A randomized controlled trial.

Iwamoto Y, Clauson P, Nishida T, Kaku K.

J Diabetes Investig. 2013 Jan 29;4(1):62-8. doi: 10.1111/j.2040-1124.2012.00240.x. Epub 2012 Sep 14.


In search of the ideal basal insulin: Does the new-generation ultra-long-acting insulin, degludec, provide the answer?

Hui E, Lam KS.

J Diabetes Investig. 2013 Jan 29;4(1):39-41. doi: 10.1111/j.2040-1124.2012.00243.x. Epub 2012 Sep 23. No abstract available.


Medium-term effects of insulin degludec on patients with type 1 diabetes mellitus.

Nakae R, Kusunoki Y, Katsuno T, Tokuda M, Akagami T, Murai K, Hamaguchi T, Miyagawa J, Namba M.

Drugs R D. 2014 Jun;14(2):133-8. doi: 10.1007/s40268-014-0048-6.


Insulin Degludec Aspart: The First Co-formulation of Insulin Analogues.

Kalra S.

Diabetes Ther. 2014 Jun;5(1):65-72. doi: 10.1007/s13300-014-0067-x. Epub 2014 May 15.


Patient safety and minimizing risk with insulin administration - role of insulin degludec.

Aye MM, Atkin SL.

Drug Healthc Patient Saf. 2014 Apr 30;6:55-67. doi: 10.2147/DHPS.S59566. eCollection 2014. Review.


Treat-to-target trials in diabetes.

Wangnoo SK, Sethi B, Sahay RK, John M, Ghosal S, Sharma SK.

Indian J Endocrinol Metab. 2014 Mar;18(2):166-74. doi: 10.4103/2230-8210.129106. Review.


Efficacy and safety of insulin degludec given as part of basal-bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26-week randomized, open-label, treat-to-target non-inferiority trial.

Davies MJ, Gross JL, Ono Y, Sasaki T, Bantwal G, Gall MA, Niemeyer M, Seino H; BEGIN BB T1 Study Group.

Diabetes Obes Metab. 2014 Oct;16(10):922-30. doi: 10.1111/dom.12298. Epub 2014 May 8.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk